Another randomized Phase III (IMspire170, NCT03273153) compared cobimetinib plus atezolizumab (PD‐L1 inhibitor) with single agent of pembrolizumab in patients with BRAF wild‐type melanoma (n = 71; 32% of combination group and 46.4% of pembrolizumab group with NRAS mutation). Here, BRAF is linked to melanoma.